by Scott Harwood | Oct 11, 2023
The U.S. Food and Drug Administration (FDA) is taking significant steps to expedite the development of novel drug and biological products for rare diseases. Support for Clinical Trials Advancing Rare Disease Therapeutics (START) aims to provide increased support and...
by Scott Harwood | Mar 13, 2023
Bernie Williams, former New York Yankee baseball player and current jazz musician, discusses the need for physicians to be aware of early signs and symptoms of various interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). IPF is a chronic,...
by Scott Harwood | Dec 19, 2022
Rebecca Silbermann, MD, MMS, of the Knight Cancer Translational Oncology Program, Oregon Health & Science University, discusses patient reported outcomes from the phase 2 GRIFFIN trial, assessing daratumumab plus lenalidomide, bortezomib, and dexamethasone...
by Scott Harwood | Sep 26, 2022
Mariana C. Castells MD, PhD, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, and Professor of Medicine, Harvard Medical School, discusses the results of TouchStone, a patient and healthcare provider (HCP) survey focused on...
by Scott Harwood | Aug 30, 2022
The U.S. Food and Drug Administration (FDA) has approved pemigatinib for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. Pemigatinib is a selective fibroblast growth factor receptor (FGFR) inhibitor and is the...
